ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
1.18%
US Dollar vs MXN
16.9724
0.00%
Brent Oil
82.765
0.00%
Bitcoin
63,142.53
0.40%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Biolase Inc (BIOL)

  7. Biolase Inc (BIOL) Noticias

BIOL Biolase Inc

0.1499
0.0015 (1.01%)
03 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Biolase Inc BIOL NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.0015 1.01% 0.1499 18:58:23
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.1488 0.1421 0.1498 0.1451 0.1484
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
08/3/202405:31EDGAR2Form PRE 14A - Other preliminary proxy statements
05/3/202405:05EDGAR2Form 8-K - Current report
27/2/202415:14EDGAR2Form 8-K - Current report
23/2/202415:05EDGAR2Form SC 13G - Statement of acquisition of beneficial..
21/2/202415:39EDGAR2Form SC 13G - Statement of acquisition of beneficial..
21/2/202406:01EDGAR2Form 8-K - Current report
15/2/202416:15EDGAR2Form 8-K - Current report
14/2/202412:10EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202423:15EDGAR2Form EFFECT - Notice of Effectiveness
13/2/202419:03EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
09/2/202407:44EDGAR2Form S-1/A - General form for registration of securities..
07/2/202405:11EDGAR2Form S-1/A - General form for registration of securities..
07/2/202405:04EDGAR2Form 8-K - Current report
30/1/202420:57EDGAR2Form S-1/A - General form for registration of securities..
29/1/202416:01EDGAR2Form 8-K - Current report
29/1/202405:30PRNUSBIOLASE REPORTS UNAUDITED REVENUE GROWTH FOR FULL YEAR 2023..
24/1/202416:21EDGAR2Form S-8 - Securities to be offered to employees in employee..
19/1/202405:09EDGAR2Form S-1 - General form for registration of securities under..
08/1/202415:05PRNUSBIOLASE ENHANCES EDUCATION OFFERINGS IN 2024 DUE TO..
03/1/202415:05PRNUSBIOLASE RECEIVES SECOND TOP WORKPLACES 2023 AWARD
29/12/202315:05EDGAR2Form 8-K - Current report
26/12/202316:22EDGAR2Form S-1 - General form for registration of securities under..
14/12/202315:05PRNUSBIOLASE RECEIVES TOP WORKPLACES 2023 AWARD
12/12/202315:05PRNUSBIOLASE Successfully Concludes Waterlase iPlus All Tissue..
08/12/202308:25EDGAR2Form 8-K - Current report
08/12/202308:23EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06/12/202312:46PRNUSBIOLASE, Inc. Announces Pricing of $1.4 Million Registered..
17/11/202315:17EDGAR2Form 8-K - Current report
09/11/202315:52EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202315:20EDGAR2Form 8-K - Current report
09/11/202315:05PRNUSBIOLASE REPORTS THIRD QUARTER FINANCIAL RESULTS; COMPANY..
08/11/202305:30PRNUSLandmark Study Performed by the Independent McGuire..
07/11/202315:05PRNUSBIOLASE TO REPORT THIRD QUARTER 2023 RESULTS ON NOVEMBER 9,..
18/10/202307:00PRNUSSWK Holdings Highlights Recent Achievements and Provides..
10/10/202314:53EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
18/9/202315:59EDGAR2Form 8-K - Current report
18/9/202315:30PRNUSBIOLASE Inc. Announces Closing of $4.5 Million Underwritten..
15/9/202316:27EDGAR2Form 424B1 - Prospectus [Rule 424(b)(1)]
15/9/202316:27EDGAR2Form 424B1 - Prospectus [Rule 424(b)(1)]
14/9/202308:08EDGAR2Form POS EX - Post-effective amendment adding exhibits to..
13/9/202322:16PRNUSBIOLASE Inc. Announces Pricing of $4.5 Million Underwritten..
13/9/202320:25EDGAR2Form S-1MEF - Registration adding securities to prior Form..
12/9/202314:26EDGAR2Form SC 13G - Statement of acquisition of beneficial..
11/9/202316:09EDGAR2Form S-1/A - General form for registration of securities..
30/8/202316:31EDGAR2Form S-1/A - General form for registration of securities..
10/8/202315:53EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202315:07EDGAR2Form 8-K - Current report
10/8/202315:05PRNUSBIOLASE REPORTS RECORD CONSUMABLE SALES AS TOTAL SECOND..
02/8/202315:05PRNUSBIOLASE TO REPORT SECOND QUARTER 2023 RESULTS ON AUGUST 10,..
26/7/202315:38EDGAR2Form 8-K - Current report

Su Consulta Reciente

NASDAQ
BIOL
Biolase
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados